ES2558875T3 - Composición anticonceptiva - Google Patents
Composición anticonceptiva Download PDFInfo
- Publication number
- ES2558875T3 ES2558875T3 ES07718599.9T ES07718599T ES2558875T3 ES 2558875 T3 ES2558875 T3 ES 2558875T3 ES 07718599 T ES07718599 T ES 07718599T ES 2558875 T3 ES2558875 T3 ES 2558875T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutically acceptable
- contraceptive
- compound
- dendrimer compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 230000002254 contraceptive effect Effects 0.000 title claims abstract description 64
- 239000003433 contraceptive agent Substances 0.000 title claims abstract description 58
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 239000000412 dendrimer Substances 0.000 claims abstract description 30
- 229920000736 dendritic polymer Polymers 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 241001465754 Metazoa Species 0.000 claims abstract description 20
- 239000012453 solvate Substances 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 11
- 239000003085 diluting agent Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 11
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 11
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 15
- 230000000845 anti-microbial effect Effects 0.000 claims description 10
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Chemical class 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Chemical class 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000004714 phosphonium salts Chemical class 0.000 claims description 2
- 239000011591 potassium Chemical class 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Chemical class 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002023 chloroprocaine Drugs 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 229910052725 zinc Chemical class 0.000 claims 1
- 239000011701 zinc Chemical class 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 19
- 229940068196 placebo Drugs 0.000 description 18
- 239000000902 placebo Substances 0.000 description 18
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 16
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 16
- 210000002257 embryonic structure Anatomy 0.000 description 14
- 229920000126 latex Polymers 0.000 description 14
- 239000004816 latex Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 230000001150 spermicidal effect Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000700584 Simplexvirus Species 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 108010037442 SPL7013 Proteins 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 5
- 230000003641 microbiacidal effect Effects 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 230000009027 insemination Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- -1 coatings Substances 0.000 description 3
- 229940124558 contraceptive agent Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940124561 microbicide Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000934 spermatocidal agent Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000001521 two-tailed test Methods 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 102100034405 Headcase protein homolog Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 101001066896 Homo sapiens Headcase protein homolog Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 241001534216 Klebsiella granulomatis Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 241000517304 Pthirus pubis Species 0.000 description 1
- 241000509416 Sarcoptes Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 229920006173 natural rubber latex Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/754—Dendrimer, i.e. serially branching or "tree-like" structure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006901474 | 2006-03-22 | ||
| AU2006901474A AU2006901474A0 (en) | 2006-03-22 | Composition | |
| PCT/AU2007/000352 WO2007106944A1 (en) | 2006-03-22 | 2007-03-21 | Contraceptive composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2558875T3 true ES2558875T3 (es) | 2016-02-09 |
Family
ID=38521950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07718599.9T Active ES2558875T3 (es) | 2006-03-22 | 2007-03-21 | Composición anticonceptiva |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8193248B2 (enExample) |
| EP (1) | EP1996209B1 (enExample) |
| JP (1) | JP5322918B2 (enExample) |
| CN (1) | CN101405010B (enExample) |
| AU (1) | AU2007229268B2 (enExample) |
| CA (1) | CA2640978C (enExample) |
| ES (1) | ES2558875T3 (enExample) |
| WO (1) | WO2007106944A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100324146A1 (en) * | 2008-02-22 | 2010-12-23 | Starpharma Pty Ltd | Dendrimeric Enzyme Inhibitors |
| WO2010033188A2 (en) * | 2008-09-16 | 2010-03-25 | Playtex Products, Llc. | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same |
| US20110077263A1 (en) * | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
| US20110086044A1 (en) * | 2009-09-29 | 2011-04-14 | University Of Southern California | Compositions and Methods to Inhibit HPV Infection |
| CA2836168C (en) * | 2011-05-16 | 2019-09-24 | Starpharma Pty Ltd | Method of treatment or prophylaxis of bacterial vaginosis |
| US20140315795A1 (en) | 2012-10-26 | 2014-10-23 | Nlife Therapeutics, S.L. | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types |
| WO2014113693A1 (en) * | 2013-01-18 | 2014-07-24 | University Of Utah Research Foundation | Modified release osmotic pump for ph-responsive intravaginal drug delivery |
| WO2016007538A1 (en) * | 2014-07-07 | 2016-01-14 | Prophylaxis, Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| US11071745B2 (en) | 2014-07-07 | 2021-07-27 | Elian Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| GB201617063D0 (en) * | 2016-10-07 | 2016-11-23 | Cambridge Design Research Llp | Condoms |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| GB9407812D0 (en) | 1994-04-20 | 1994-06-15 | Nycomed Salutar Inc | Compounds |
| AUPM623994A0 (en) * | 1994-06-15 | 1994-07-07 | Biomolecular Research Institute Limited | Antiviral dendrimers |
| AUPO104496A0 (en) | 1996-07-17 | 1996-08-08 | Biomolecular Research Institute Limited | Angiogenic inhibitory compounds |
| US6191120B1 (en) * | 1998-03-25 | 2001-02-20 | Wayne Hughes Institute | Spermicidally active 5-halo-6-alkoxy-5,6-dihydro-2′,3′-dideoxy-uridines and their pharamaceutical compositions |
| US6192887B1 (en) * | 1998-05-19 | 2001-02-27 | The Pennsylvania State University | Broad spectrum microbicidal and spermicidal compositions and methods having activity against sexually transmitted agents including papillomaviruses |
| AUPP584398A0 (en) * | 1998-09-14 | 1998-10-08 | Starpharma Limited | Inhibition of toxic materials or substances |
| AUPP584298A0 (en) * | 1998-09-14 | 1998-10-08 | Starpharma Limited | Antimicrobial and antiparasitic agents |
| CA2402520A1 (en) * | 2000-03-13 | 2001-09-20 | Kenneth Beckman | Biocidal methods and compositions |
| US6471968B1 (en) | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
| AUPR412801A0 (en) * | 2001-03-30 | 2001-05-03 | Starpharma Limited | Agent for the prevention and treatment of sexually transmitted disease s - I |
| CA2346188A1 (en) * | 2001-05-02 | 2002-11-02 | Bradley Benson | Male sexual aid device |
| AU2003225636A1 (en) | 2002-03-05 | 2003-09-22 | Ramot At Tel-Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein |
| JP2005527546A (ja) * | 2002-03-26 | 2005-09-15 | イースタン ヴァージニア メディカル スクール | 局所用殺菌剤および避妊薬としてのスラミンおよびその誘導体 |
-
2007
- 2007-03-21 US US12/294,024 patent/US8193248B2/en not_active Expired - Fee Related
- 2007-03-21 WO PCT/AU2007/000352 patent/WO2007106944A1/en not_active Ceased
- 2007-03-21 CA CA2640978A patent/CA2640978C/en not_active Expired - Fee Related
- 2007-03-21 ES ES07718599.9T patent/ES2558875T3/es active Active
- 2007-03-21 AU AU2007229268A patent/AU2007229268B2/en not_active Ceased
- 2007-03-21 EP EP07718599.9A patent/EP1996209B1/en not_active Not-in-force
- 2007-03-21 CN CN2007800100366A patent/CN101405010B/zh active Active
- 2007-03-21 JP JP2009500668A patent/JP5322918B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009530316A (ja) | 2009-08-27 |
| EP1996209A1 (en) | 2008-12-03 |
| CN101405010A (zh) | 2009-04-08 |
| CN101405010B (zh) | 2013-03-06 |
| US8193248B2 (en) | 2012-06-05 |
| EP1996209A4 (en) | 2010-04-21 |
| CA2640978C (en) | 2016-01-19 |
| WO2007106944A1 (en) | 2007-09-27 |
| AU2007229268A1 (en) | 2007-09-27 |
| CA2640978A1 (en) | 2007-09-27 |
| EP1996209B1 (en) | 2015-11-04 |
| US20090275507A1 (en) | 2009-11-05 |
| AU2007229268B2 (en) | 2013-01-10 |
| JP5322918B2 (ja) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2558875T3 (es) | Composición anticonceptiva | |
| ES2357474T3 (es) | Composiciones y su uso para atrapar e inactivar microbios patógenos y espermatoziodes. | |
| JP2845325B2 (ja) | 長時間持続性の避任用坐薬組成物および使用方法 | |
| ES2482190T3 (es) | Uso de oligómeros de ácido láctico en el tratamiento de infecciones ginecológicas | |
| AU2001243431A1 (en) | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa | |
| JP2022070924A (ja) | アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 | |
| JP6738573B2 (ja) | 避妊殺菌剤の効果を増強するための組成物および方法 | |
| Xie et al. | A trifunctional contraceptive gel enhances the safety and quality of sexual intercourse | |
| ZANEVELD et al. | Properties of a New, Long‐Lasting Vaginal Delivery System (LASRS) for Contraceptive and Antimicrobial Agents | |
| US20090118352A1 (en) | Broad spectrum microbicidal and spermicidal compositions and methods | |
| AU2013277007B2 (en) | Aqueous moisturizers and lubircants and uses thereof | |
| Lee et al. | Development of 17BIPHE2 into a vaginal multipurpose prevention technology (MPT) agent with spermicidal effects and microbicidal activity against Neisseria gonorrhoeae | |
| Raoult et al. | Hydrogels in Contraceptive Applications and Their Mechanisms of Action | |
| HK40021110A (en) | Compositions and methods for enhancing the efficacy of contraceptive microbicides | |
| OA17704A (en) | Compositions and methods for enhancing the efficacy of contraceptive microbicides. |